AMH Equity Ltd Grows Holdings in Precipio, Inc. $PRPO

AMH Equity Ltd lifted its stake in shares of Precipio, Inc. (NASDAQ:PRPO) by 370.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 131,100 shares of the biotechnology company’s stock after acquiring an additional 103,210 shares during the quarter. Precipio comprises about 2.9% of AMH Equity Ltd’s investment portfolio, making the stock its 9th biggest holding. AMH Equity Ltd owned 8.09% of Precipio worth $2,332,000 at the end of the most recent reporting period.

Precipio Trading Down 2.1%

NASDAQ:PRPO opened at $23.50 on Friday. The company’s 50 day moving average is $23.49 and its 200-day moving average is $19.22. The company has a quick ratio of 1.10, a current ratio of 1.27 and a debt-to-equity ratio of 0.06. Precipio, Inc. has a 12 month low of $3.90 and a 12 month high of $28.50. The firm has a market cap of $41.13 million, a price-to-earnings ratio of -28.66 and a beta of 1.12.

Precipio (NASDAQ:PRPO) last issued its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.05) EPS for the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.The business had revenue of $6.77 million during the quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research report on Wednesday, October 8th. Wall Street Zen downgraded Precipio from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.